Authorized generics take strikes from GPhA, Dems

Share this article:
Bad news for authorized generics on two fronts.

First, a Generic Pharmaceutical Association (GPhA) study showed that authorized generics yield consumers few cost savings, and that any such savings come from higher brand product prices, not lower generic prices.

And second, three Democratic senators announced a bill to ban them outright.

The GPhA study concluded that when authorized generics are marketed during a 180-day exclusivity period for an independent generic company, they significantly reduce the incentives for independent generic firms to challenge brand-name patents and develop non-infringing processes.

The findings challenged the methodology, analysis and conclusions of a recent study by the Pharmaceutical Research and Manufacturers of America that reported discounts off brand prices up to 15.8% greater in markets with authorized generics than in those without them.

Meanwhile, Senate bill S. 3695 was introduced to ban “authorized generics” from launching during the first approved generic applicant's 180-day marketing exclusivity period. Backed by Senators John D. Rockefeller IV (D-WV), Charles Schumer (D-NY) and Patrick Leahy (D-VT), the measure is intended to prevent brand drug makers from re-packaging previously approved drugs as generics in an attempt to undermine generic competition.

“Authorized generics are a sham,” said Rockefeller. “They are nothing more than repackaged prescription drugs without true generic's lower cost,” and eliminate billions in prescription drug savings.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...